LillyDirect self-pay ladder confirmed at $299 to $449 with a refill condition, and $499 to $699 without

A pricing review published September 5, 2026 corrected earlier reports on LillyDirect's Zepbound self-pay program, confirming a tiered pricing ladder that depends on a 45-day refill window most secondary coverage had dropped ^[1].

Under the confirmed terms, LillyDirect charges $299 a month for the 2.5 mg starting dose, $399 for 5 mg, and $449 for doses from 7.5 mg to 15 mg, but only when a patient refills within 45 days of the prior fill ^[1][2]. Miss that window, and the price for 7.5 mg rises to $499, while 10 mg, 12.5 mg and 15 mg jump to $699 ^[1][2]. These prices apply to both single-dose vials and the Zepbound KwikPen, a multi-dose pen that launched February 23, 2026 and holds 10 mg in 2.4 mL, delivering four weekly doses ^[1].

The correction matters because the review's earlier version had reported different figures entirely, including a flat $349 or $499 LillyDirect price and a $1,499 three-month bundle, none of which appear in Lilly's actual 2026 terms ^[1]. The publisher stated those figures have been removed and replaced with the sourced numbers above ^[1]. A second tracker separately lists LillyDirect prices as "$299 to $449 a month depending on dose" and notes that $299 applies to the starter doses, with the price climbing toward $449 as patients titrate up over several weeks ^[2].

The refill-timing detail changes the effective monthly cost by hundreds of dollars at maintenance doses. A patient on 10 mg or 15 mg who refills on time pays $449, but the same dose costs $699 without that timely refill — a $250 monthly swing, or roughly $3,000 a year ^[1].

Why it matters for patients

Most people taking Zepbound long-term end up at a maintenance dose in the 7.5 mg to 15 mg range, where this refill condition applies. For that group, the difference between $449 and $699 a month is not a rounding error — it is the difference between roughly $5,400 and $8,400 a year for the drug alone ^[1]. Patients relying on secondary coverage of LillyDirect pricing, rather than Lilly's own published terms, may have budgeted using numbers that were incorrect ^[1].

The LillyDirect self-pay ladder is separate from Lilly's Zepbound Savings Card, which offers a $25 price to commercially insured patients whose plan covers Zepbound, subject to a $100 per 1-month fill cap and $1,300 annual cap in 2026, down from $150 and $1,950 in 2025 ^[1]. LillyDirect self-pay is intended for patients without insurance coverage for Zepbound, including those on Medicaid, TRICARE, VA and DoD, who remain excluded from the savings card ^[1]. Medicare enrollees have a separate option: the Medicare GLP-1 Bridge, which caps the Zepbound KwikPen at $50 a month with prior authorization from July 1, 2026 through December 31, 2027 ^[1][2].

One tracker also notes that compounded tirzepatide, which is not FDA-approved and not Zepbound, is priced separately and starts lower than LillyDirect in some cases, though formulations can differ from the approved drug ^[1][2].

What happens next

The 2026 Zepbound Savings Card terms are set to expire December 31, 2026, and Lilly typically publishes new terms each January ^[1]. The Medicare GLP-1 Bridge is scheduled to run through December 31, 2027 ^[1][2]. Patients checking their own price are advised by one source to ask a pharmacy to run a test claim before filling, since card-entry errors, prior-authorization delays and prescriptions written for the wrong brand name are common causes of price mismatches at the counter ^[1].